MetaCap

Arbutus Biopharma (ABUS) vs Apnimed (APMD)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Apnimed is the larger company by market cap ($669.8 million vs $616.2 million), about 1.1 times the size. On valuation, Apnimed trades at a lower trailing P/E (1.2x vs 3.6x for Arbutus Biopharma).

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ABUS-7.37%APMD-35.64%
+34%-7%-47%
Jul 31, 20261 yearNov 20, 2026
ABUS-7.37%APMD-35.64%
+30%-6%-43%
Jul 27, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ABUS versus APMD key metrics
MetricABUSAPMD
Share price$4.02$16.09
Market cap$616.24M$669.84M
1-day change-1.23%-6.70%
YTD return-16.42%—
1-year return-6.73%—
5-year return+28.43%—
P/E ratio (TTM)3.591.21
EPS (TTM)$1.12$13.34
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$14.08M—
Revenue growth (YoY)+128.21%—
Net income (latest FY)$-33.50M—
Operating margin-270.96%—
Net margin-237.88%—
52-week high$5.45$35.29
52-week low$3.50$13.88
Distance from 52-week high-26.24%-54.41%
Analyst consensusnonestrong_buy
Avg. price target upside+32.34%+210.75%
Average volume4.98M458.58K
Shares outstanding153.29M41.63M
Employees19112
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Arbutus Biopharma trades at a higher earnings multiple (3.6x vs 1.2x trailing P/E).

About Arbutus Biopharma

ABUS stock →

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1.

Health Care · Biotechnology: Pharmaceutical Preparations · 19 employees

About Apnimed

APMD stock →

Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets.

Health Care · Biotechnology: Pharmaceutical Preparations · 112 employees

ABUS vs APMD FAQ

Which is bigger, Arbutus Biopharma or Apnimed?

Apnimed (APMD) is larger, with a market capitalization of $669.84M compared with $616.24M for Arbutus Biopharma (ABUS).

Which has the lower P/E ratio, ABUS or APMD?

APMD has the lower trailing P/E at 1.2, versus 3.6 for ABUS. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Are Arbutus Biopharma and Apnimed in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons